ST-193

Category	Arenavirus
CAS	489416-12-8
Description	ST-193 is a potent, broad-spectrum small-molecule inhibitor of arenavirus entry and exhibits submicromolar antiviral activity in vitro. ST-193 inhibits Guanarito, Junin, Lassa and Machupo virus with IC50 values of 0.44, 0.62, 1.4 and 3.1 nM, respectively.

Quotation Now

Product Information

Synonyms	1-(4-methoxyphenyl)-N-[(4-propan-2-ylphenyl)methyl]benzimidazol-5-amine; ST-193; ST 193; ST193
IUPAC Name	1-(4-methoxyphenyl)-N-[(4-propan-2-ylphenyl)methyl]benzimidazol-5-amine
Molecular Weight	371.47
Molecular Formula	C24H25N3O
Canonical SMILES	CC(C)C1=CC=C(C=C1)CNC2=CC3=C(C=C2)N(C=N3)C4=CC=C(C=C4)OC
InChI	1S/C24H25N3O/c1-17(2)19-6-4-18(5-7-19)15-25-20-8-13-24-23(14-20)26-16-27(24)21-9-11-22(28-3)12-10-21/h4-14,16-17,25H,15H2,1-3H3
InChIKey	JPSZEXYTKSIPDW-UHFFFAOYSA-N
Boiling Point	562.5±60.0 ℃ at 760 Torr
Flash Point	294.0±32.9 °C
Purity	99.86%
Density	1.12±0.1 g/cm3
Solubility	DMSO: ≥ 150 mg/mL
Appearance	Off-white to pink (Solid)
Storage	Store in a cool and dry place (or refer to the Certificate of Analysis).
Animal Admin	Guinea pigs: ST-193 is formulated as a solution in 32% (w/v) 2-hydroxypropyl-β-cyclodextrin (HP-β-CD). Female Hartley guinea pigs are injected intraperitoneally with a 10 mg/mL solution of ST-193 at a volume of either 2.5 mL per kg of body weight (25 mg/kg) or 10 mL per kg (100 mg/kg). Four animals per dose are used, with blood samples collected from two animals per dose at each time point in alternating fashion. Blood samples are obtained at the indicated time points (4-24 h).
Complexity	469
Exact Mass	371.199762429
Index Of Refraction	1.609
In Vitro	ST-193 inhibits LASV pseudotypes with an IC50 of 1.6 nM. ST-193 inhibits pseudotypes generated with other arenavirus envelopes as well, including the remaining four commonly associated with hemorrhagic fever (IC50s for Junín, Machupo, Guanarito, and Sabiá were in the 0.2 to 12 nM range) but exhibits no antiviral activity against pseudotypes incorporating either the GP from the LASV-related arenavirus lymphocytic choriomeningitis virus or the unrelated G protein from vesicular stomatitis virus, at concentrations of up to 10 μM.
In Vivo	ST-193 is found to be tolerated well when administered daily as an intraperitoneal injection of either 25 or 100 mg/kg/day for 14 days. ST-193-treated animals exhibit fewer signs of disease and enhance survival when compared to the ribavirin or vehicle groups. Body temperatures in all groups are elevated by day 9, but returned to normal by day 19 postinfection in the majority of ST-193-treated animals. ST-193 treatment mediates a 2- to 3-log reduction in viremia relative to vehicle-treated controls. The overall survival rate for the ST-193-treated guinea pigs is 62.5% (10/16) compared with 0% in the ribavirin (0/8) and vehicle (0/7) groups.
Target	IC50: 0.44 nM (Guanarito), 0.62 nM (Junin), 1.4 nM (Lassa) and 3.1 nM (Machupo)
Vapor Pressure	0.0±1.5 mmHg at 25°C
XLogP3-AA	5.7